|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
2.94/3.63
|
企业价值
12.98B
|
资产负债 |
每股账面净值
11.29
|
现金流量 |
现金流量率
0.01
|
损益表 |
收益
1.70B
|
每股收益
22.24
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/13 16:29 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide. |